Be sure to check out Dr. Vikas Gupta as he shares his work at #ESCMIDGlobal2026!
He highlights findings which demonstrate that remnant suspension from ASTar enabled high performance pathogen ID & genotypic testing with future potential to reduce costs related to automated multiplex platforms 🔬
SCACM Spring Meeting workshop | April 14, 2–3 pm ET
Emilia Marrero-Greene (Lakeland Regional Health) presents a laboratory evaluation of rapid AST and ASTar® and potential impact on lab processes and patient outcomes.
Real‑world laboratory experience
🔗 scacm27.wildapricot.org/2026_Spring_...
#SCACM
Our mission is to make rapid, high-quality AST accessible to clinical teams worldwide. We are committed to advancing the fight against AMR and supporting hospitals in delivering timely, precise infectious disease care.
Every hour counts in sepsis care. Earlier, targeted therapy improves patient outcomes and strengthens antimicrobial stewardship by helping protect the effectiveness of antibiotics for the future.
ASTar® rapid AST instrument used for fast antimicrobial susceptibility testing.
We’re Q-linea, delivering rapid phenotypic AST to infectious disease care. With ASTar®, susceptibility results from positive blood cultures are available in ~6 hours, giving clinical teams the clarity to act earlier and more precisely. #AMR #ClinicalMicrobiology #IDSky